Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 22c; Offers FY23 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts CSTL Hot Sheet
Join SI Premium – FREE
Castle Biosciences Inc. (NASDAQ: CSTL) reported Q2 EPS of ($0.70), $0.22 better than the analyst estimate of ($0.92). Revenue for the quarter came in at $50.14 million versus the consensus estimate of $44.24 million.
GUIDANCE:
Castle Biosciences Inc. sees FY2023 revenue of $180 million, versus the consensus of $174.5 million.
For earnings history and earnings-related data on Castle Biosciences Inc. (CSTL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H2O America (HTO) Misses Q3 EPS by 16c ; Offers Guidance
- Dorman Products (DORM) Tops Q3 EPS by 8c, Offers Guidance
- JetBlue Airways (JBLU) Misses Q3 EPS by 6c, Misses on Revenue
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
